DMRA earnings date and last-quarter result: last quarter miss, P/E -0.17. Updated 2026-07-23.
Damora Therapeutics (DMRA) Research Hub
Damora Therapeutics (DMRA) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 21.26 USD (+0.81%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.17, market cap 1.84B. This hub links to the full technical, earnings and options research available for DMRA.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 21.26 USD (+0.81%) |
| 52-week range | 17.49 USD – 34.89 USD |
| Trend regime | Range |
| 14-day RSI | 59.7 (Bullish) |
| Trailing P/E | -0.17 |
| Market cap | 1.84B |
| Dividend yield | 0.00% |
Available research for DMRA
Covered Call on DMRA: how it works, illustrative setup around the real 21.26 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on DMRA: how it works, illustrative setup around the real 21.26 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on DMRA: how it works, illustrative setup around the real 21.26 USD price, max profit/loss, breakeven and when to use it. Educational.
DMRA technical analysis: range, last 21.26 USD, RSI 59.7, 52w range 17.49 USD–34.89 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is DMRA in?
Damora Therapeutics (DMRA) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is DMRA in an uptrend or downtrend?
As of 2026-10-26, DMRA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is DMRA's trailing P/E ratio?
DMRA's trailing P/E is -0.17, with a market cap of 1.84B. See the earnings research page for full valuation detail.